Home › Compare › BYCRF vs ABBV
BYCRF yields 2.34% · ABBV yields 3.06%● Live data
📍 BYCRF pulled ahead of the other in Year 3
Combined, BYCRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BYCRF + ABBV for your $10,000?
BayCurrent Consulting, Inc. provides consulting services in Japan. The company provides engaged in designing and implementing strategy/business strategy, globalization, m&a/jv/alliances, innovation/new business development, turn-around, innovation/new business development, overseas expansion, global resource utilization, global governance design, change towards capturing inbound demand, marketing and sales strategy, and business due diligence.It offers DX-based high level planning, digital department launch, blockchain utilization, business model DX, designing thinking/agile operations, digital marketing, AI/IoT implementation, DX strategy/roadmap formulation, digital human resource development, fintech/insurtech, operation DX, and lean start-ups services. Additionally, the company provides procurement cost reduction, business process re-engineering, supply chain management, customer relationship management, risk management, value chain transformation, governance/management design, operation reform/standardization, and leadership training services. Further, it offers IT strategy, IT governance, IT cost optimization, IT organizational improvement, IT talent development, PMO, IT architecture, system design/ development, and IT asset evaluation services. The company serves financial, high-tech/telecommunication, media/entertainment, industrial/distribution/retail, health care, energy, and public sector industries. BayCurrent Consulting, Inc. was founded in 1998 and is based in Tokyo, Japan.
Full BYCRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.